Liver disorders more prominent with oral terbinafine
- PDF / 123,029 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 38 Downloads / 175 Views
1
Liver disorders more prominent with oral terbinafine Up to January 2008, ADRAC has received 722 adverse event reports associated with all dose forms of terbinafine. Of these, 70 reports involved hepatic reactions and 61 of these 70 reports implicated oral terbinafine as the sole suspected drug; patient age ranged from 20 to 85 years and onychomycosis was the most commonly cited reason for terbinafine use. Following terbinafine initiation, hepatic reactions developed within first month in half of the reports and within 7 weeks in 80% of the reports. Three reports described fatal liver failure, twelve reports described jaundice and ten reports described hepatitis. Of the 70 cases, 27 cases showed full recovery, 34 cases had not recovered and the outcome was unknown in nine cases. ADRAC has previously drawn attention to serious adverse reactions like blood dyscrasias associated with terbinafine.* Recently, the agency reviewed a case report of an elderly woman who developed cholestatic hepatitis during treatment with oral terbinafine.** The agency has advised healthcare professionals to prescribe oral terbinafine for the shortest time possible after topical therapy has failed. * see Reactions 1022 p3; 800967460 ** see this issue p 21; 801052465 Australian Adverse Drug Reactions Advisory Committee. Hepatic reactions with terbinafine. Australian Adverse Drug Reactions Bulletin 27: 3, No. 1, Feb 801052467 2008
0114-9954/10/1188-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 9 Feb 2008 No. 1188
Data Loading...
